Tofacitinib

Galapagos sells Jyseleca rights to Alfasigma for up to €170M plus royalties, transferring EU/UK marketing and 400 employees. Jyseleca, once a potential blockbuster, faced FDA rejection and setbacks, leading to reduced sales forecasts. The deal boosts Galapagos' cash and cost-cutting efforts, while Alfasigma expands internationally.

More than 250 branded drugs from pharmaceutical giants, including Bristol Myers Squibb, Sanofi-Pasteur, Merck, Pfizer, and others, will see price hikes in the U.S. starting Jan. 1. Pfizer alone is raising prices on over 60 drugs, with a median increase of 4.5%. The price hikes, which do not include rebates or discounts, are necessary to support investments in new medicines and address increased costs. U.S. prescription drug prices are significantly higher compared to those in similarly wealthy countries, and while annual increases have been scaled back, drug launch prices continue to rise, leading to restricted access and higher out-of-pocket costs for patients. Additional price increases are expected to be announced this month.

Pharmaceutical companies are increasing prices on over 250 brand drugs, with a median increase of 4.5%. Pfizer led with hikes on over 60 drugs, including a 3% increase for Paxlovid. Significant hikes include Leadiant Pharmaceuticals raising prices by 15-20% on specific treatments. The 2022 Inflation Reduction Act has influenced companies to adjust strategies, focusing on new drugs and treatments for rare diseases.

Drugmakers plan to raise U.S. prices on over 250 branded medications in 2025, with most increases below 10%. Pfizer, Bristol Myers Squibb, and Sanofi are among those adjusting prices, citing inflation and investment needs. The U.S. continues to pay the highest for prescription drugs globally.

Starting January 1, over 250 US medications, including Pfizer's Paxlovid and Sanofi's vaccines, will see price increases, mostly under 10%. Pfizer, Bristol Myers, and Sanofi lead with hikes between 3% to 9%. Leadiant Pharmaceuticals tops with 15-20% increases on specific treatments.

Drugmakers plan to raise US prices on over 250 branded medications in 2025, with most increases below 10%. Pfizer leads with over 60 drugs, including a 3% hike on Paxlovid. Despite reductions on some drugs, the US continues to pay the highest for prescription medicines globally.